Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2013-11-12 Earnings Release
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the filing includes a press release announcing first quarter fiscal year 2014 results. The document is short (2643 characters) and primarily serves to furnish a press release rather than containing detailed financial statements or comprehensive analysis. It explicitly states that the information is not "filed" for certain regulatory purposes and is a press release attached as an exhibit. This aligns with an Earnings Release (ER) since it announces quarterly financial results highlights. The document is not a full quarterly report (IR) because it lacks substantive financial data and analysis, nor is it a report publication announcement (RPA) because it includes the press release content itself. Therefore, the best classification is Earnings Release (ER).
2013-11-12 English
DEF 14A
Proxy Solicitation & Information Statement
2013-10-25 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text includes a press release about a regulatory event (FDA Complete Response Letter) related to a drug application. The document is short (2446 characters) and primarily serves as an announcement of this event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2013-10-18 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header 'SCHEDULE 14A' and references to 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934'. It includes detailed information about the upcoming Annual Meeting, including date, location, agenda items such as election of directors, stock option approvals, ratification of stock issuance, advisory votes on executive compensation, and appointment of auditors. It also contains biographies of director nominees and voting instructions. The document is clearly a proxy solicitation material intended to inform shareholders and solicit their votes for the Annual General Meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement of it. Therefore, the correct classification is PSI with high confidence.
2013-10-02 English
FORM 10-K
Annual Report FY 2013
2013-09-27 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and states that a press release announcing fiscal fourth quarter and fiscal year ended June 30, 2013 results was issued. The document includes the press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 2676 characters, which is relatively short and consistent with a report announcing results rather than the full earnings release or quarterly report. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) correspond to an Earnings Release (ER). The document is not the full Annual Report (10-K) or Interim Report (IR), nor is it a Regulatory Filing (RNS) since it contains substantive information about earnings results. Therefore, the best classification is Earnings Release (ER).
2013-09-25 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.